Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Muz, Barbara ^a   Azab, Feda ^a   De La Puente, Pilar ^a   Rollins, Scott ^b   Alvarez, Richard ^b   Kawar, Ziad ^b   Azab, Abdel Kareem ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Selexys Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MONOCLONAL ANTIBODY; P SELECTIN ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; P SELECTIN GLYCOPROTEIN LIGAND 1 ANTIBODY; PADGEM PROTEIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; P-SELECTIN LIGAND PROTEIN; SELP PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENDOTHELIUM; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BORTEZOMIB; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MULTIPLE MYELOMA; P-SELECTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945898637     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/417586     Document Type: Article

References (26)

1. P. de la Puente, B. Muz, F. Azab, M. Luderer, and A. K. Azab, "Molecularly targeted therapies in multiple myeloma," Leukemia Research and Treatment, vol. 2014,Article ID 976567, 8 pages, 2014.
2. P. de la Puente and A. K. Azab, "Contemporary drug therapies for multiple myeloma," Drugs of Today, vol. 49, no. 9, pp. 563-573, 2013.
3. J. S. Damiano, A. E. Cress, L. A. Hazlehurst, A. A. Shtil, and W. S. Dalton, "Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in humanmyeloma cell lines," Blood, vol. 93, no. 5, pp. 1658-1667, 1999.
4. A. K. Azab, J. M. Runnels, C. Pitsillides et al., "CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy," Blood, vol. 113, no. 18, pp. 4341-4351, 2009.
5. A. K. Azab, F. Azab, S. Blotta et al., "RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma," Blood, vol. 114, no. 3, pp. 619-629, 2009.
6. A. K. Azab, P. Quang, F. Azab et al., "P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment," Blood, vol. 119, no. 6, pp. 1468-1478, 2012.
7. Y. Alsayed, H. Ngo, J. Runnels et al., "Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing inmultiplemyeloma," Blood, vol. 109, no. 7, pp. 2708-2717, 2007.
8. M. P. Bevilacqua and R. M. Nelson, "Selectins," The Journal of Clinical Investigation, vol. 91, no. 2, pp. 379-387, 1993.
9. S. Chen, R. Alon, R. C. Fuhlbrigge, and T. A. Springer, "Rolling and transient tethering of leukocytes on antibodies reveal specializations of selectins," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 3172-3177, 1997.
10. R. P. McEver and R. D. Cummings, "Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment," The Journal of Clinical Investigation, vol. 100, no. 3, pp. 485-491, 1997.
11. A. Leppänen, T. Yago, V. I. Otto, R. P. McEver, and R. D. Cummings, "Model glycosulfopeptides from P-selectin glycoprotein ligand-1 require tyrosine sulfation and a core 2-branched Oglycan to bind to L-selectin,"The Journal of Biological Chemistry, vol. 278, no. 29, pp. 26391-26400, 2003.
12. K. L. Moore, K. D. Patel, R. E. Bruehl et al., "P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin," The Journal of Cell Biology, vol. 128, no. 4, pp. 661-671, 1995.
13. W. S. Somers, J. Tang, G. D. Shaw, and R. T. Camphausen, "Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P-and E-seiectin bound to SLe(X) and PSGL-1," Cell, vol. 103, no. 3, pp. 467-479, 2000.
14. I. P. Witz, "The selectin-selectin ligand axis in tumor progression," Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 19-30, 2008.
15. S. R. Barthel, J. D. Gavino, L. Descheny, and C. J. Dimitroff, "Targeting selectins and selectin ligands in inflammation and cancer," Expert Opinion on Therapeutic Targets, vol. 11, no. 11, pp. 1473-1491, 2007.
16. C. A. St. Hill, "Interactions between endothelial selectins and cancer cells regulate metastasis," Frontiers in Bioscience, vol. 16, no. 8, pp. 3233-3251, 2011.
17. K. V. Honn, D. G. Tang, and J. D. Crissman, "Platelets and cancermetastasis: a causal relationship?" Cancer andMetastasis Reviews, vol. 11, no. 3-4, pp. 325-351, 1992.
18. J.-L. Chen, W.-X. Chen, J.-S. Zhu et al., "Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function,"World Journal of Gastroenterology, vol. 9, no. 7, pp. 1607-1610, 2003.
19. C. F. J. M. Peeters, T. J. M. Ruers, J. R. Westphal, and R. M. W. de Waal, "Progressive loss of endothelial P-selectin expression with increasing malignancy in colorectal cancer," Laboratory Investigation, vol. 85, no. 2, pp. 248-256, 2005.
20. S. Z. Aki, G. T. S?ucak, H. Pas?ao?glu et al., "Thrombopoietic cytokine andP-selectin levels inpatientswithmultiplemyeloma undergoing autologous stem cell transplantation: decrease in posttransplantation P-selectin levels might predict the degree of maximum response," Clinical Lymphoma and Myeloma, vol. 9, no. 3, pp. 229-233, 2009.
21. F. Atalay, E. B. Ates?o?glu, S. Y?ld?z, T. Firatl?-Tuglular, S. Karakus?, and M. Bay?k, "Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma," Clinical Lymphoma Myeloma and Leukemia, vol. 15, no. 3, pp. 164-170, 2015.
22. A. M. Florena, C. Tripodo, L. Miceli, S. Ingrao, R. Porcasi, and V. Franco, "Identification of CD162 in plasma-cell dyscrasia," The Lancet Oncology, vol. 6, no. 8, p. 632, 2005.
23. Y. Zheng, J. Yang, J. Qian et al., "PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma," Leukemia, vol. 27, no. 3, pp. 702-710, 2013.
24. J. Chang, J. T. Patton, A. Sarkar, B. Ernst, J. L. Magnani, and P. S. Frenette, "GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice," Blood, vol. 116, no. 10, pp. 1779-1786, 2010.
25. A. K. Azab, F. Azab, P. Quang et al., "FGFR3 is overexpressed Waldenström macroglobulinemia and its inhibition by dovitinib induces apoptosis and overcomes stroma-induced proliferation," Clinical Cancer Research, vol. 17, no. 13, pp. 4389-4399, 2011.
26. C. Tripodo, A. M. Florena, P. Macor et al., "P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma," Current Cancer Drug Targets, vol. 9, no. 5, pp. 617-625, 2009.